• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Firefly Neuroscience Inc.

    5/20/26 8:30:46 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology
    Get the next $AIFF alert in real time by email
    S-8 1 ea0291419-s8_firefly.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on May 20, 2026

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933

     

    FIREFLY NEUROSCIENCE, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   54-1167364
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    1100 Military Road, Kenmore, NY   14217
    (Address of Principal Executive Offices)   (Zip Code)

     

    Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan,

    as amended

    (Full title of the plan)

     

    Greg Lipschitz, Chief Executive Officer

    1100 Military Road

    Kenmore, NY 14217

    (888) 237-6412

     

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Louis A. Bevilacqua, Esq.

    Bevilacqua PLLC

    800 Connecticut Ave., N.W., Suite 300

    Washington, DC  20006

    (202) 869-0888

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐ 
    Non-accelerated filer ☒  Smaller reporting company ☒ 
      Emerging growth company ☐ 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”) is filed by Firefly Neuroscience, Inc., a Delaware corporation (the “Registrant”), to register additional shares of common stock, par value $0.0001 per share (the “common stock”), available for issuance pursuant to Amendment No. 1 (the “Amendment”) to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (as amended by the Amendment, the “Plan”). Pursuant to Section 5.3 of the Plan (hereinafter referred to as the “Evergreen Provisions”), the number of common stock with respect to which awards may be granted under the Plan will be increased on the first day of each calendar year beginning in 2026 and continuing until (and including) 2035, in accordance with a formula set forth in the Plan. Based on the foregoing, the additional securities registered hereby consist of 556,343 common stock that are added to the award pool of the Plan, effective from January 1, 2026, pursuant to the Plan’s Evergreen Provisions, which were not previously registered under the currently effective registration statement on Form S-8 (File No. 333-287455) filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 21, 2025 (the “First Prior Registration Statement”) and the currently effective registration statement on Form S-8 (File No. 333-291609)  filed with the SEC on November 18, 2025 (the “Second Prior Registration Statement”, and together with the First Prior Registration Statement, the “Prior Registration Statements”).

     

    The contents of the Prior Registration Statements are hereby incorporated by reference pursuant to General Instruction E to Form S-8, except that the section captioned “Reoffer Prospectus” of each of the Prior Registration Statements is not incorporated by reference herein, and except to the extent otherwise supplemented, amended, modified, or superseded by the information set forth in this Registration Statement.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information specified in this Part I will be sent or given to the persons participating in the Plan, as specified by Rule 428(b)(1) under the Securities Act. In accordance with the instructions to Part I of Form S-8, such documents need not be filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 promulgated under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    1

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by Firefly Neuroscience, Inc., a Delaware corporation (the “Registrant”), with the Securities and Exchange Commission (the “SEC”) are incorporated by reference into this Registration Statement:

     

    (a)The Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026;

     

    (b)The Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the SEC on May 13, 2026;

     

    (c)The Current Reports on Form 8-K (and any amendments thereto on Form 8-K/A) filed with the SEC on February 4, 2026, March 12, 2026, April 22, 2026, and May 12, 2026 (other than information furnished and not filed); and

     

    (d)The description of the common stock contained in Exhibit 4.1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026, including any amendment or report filed for the purpose of updating such description.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement on Form S-8 (this “Registration Statement”) and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. 

     

    II-1

     

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
    5.1*   Opinion of Bevilacqua PLLC
    23.1*   Consent of CBIZ Canada, LLP (formerly known as Marcum Canada, LLP)
    23.2*   Consent of Bevilacqua PLLC (included in Exhibit 5.1)
    24.1*   Power of Attorney (included on the signature page of this Registration Statement)
    99.1   Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on August 12, 2024)
    99.2   Amendment No. 1 to Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 99.2 to the Registration Statement on Form S-8, filed with the SEC on November 18, 2025)
    99.3   Form of Nonqualified Stock Option Agreement (incorporated herein by reference to Exhibit 99.3 to the Registration Statement on Form S-8, filed with the SEC on November 18, 2025)
    99.4   Form of Incentive Stock Option Agreement (incorporated herein by reference to Exhibit 99.4 to the Registration Statement on Form S-8, filed with the SEC on November 18, 2025)
    99.5   Form of Deferred Stock Unit Agreement (incorporated herein by reference to Exhibit 99.6 to the Registration Statement on Form S-8, filed with the SEC on November 18, 2025)
    99.6   Form of Restricted Stock Unit Agreement (incorporated herein by reference to Exhibit 99.14 to the Registration Statement on Form S-8, filed with the SEC on November 18, 2025)
    99.7   Form of Restricted Stock Award Agreement (incorporated herein by reference to Exhibit 99.19 to the Registration Statement on Form S-8, filed with the SEC on November 18, 2025)
    107*   Calculation of Filing Fee Table

     

     

    *Filed herewith.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Kenmore, State of New York, on May 20, 2026.

     

        FIREFLY NEUROSCIENCE, INC.
       
      By:  /s/ Greg Lipschitz
        Greg Lipschitz
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Greg Lipschitz and Paul Krzywicki, and each of them, individually, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Greg Lipschitz   Chief Executive Officer   May 20, 2026
    Greg Lipschitz   (principal executive officer) and Director    
             
    /s/ Paul Krzywicki   Chief Financial Officer   May 20, 2026
    Paul Krzywicki   (principal financial officer and principal accounting officer)    
             
    /s/ David DeCaprio   President, Chief Operating Officer, and Director   May 20, 2026
    David DeCaprio        
             
    /s/ Arun Menawat     Chairman of the Board of Directors   May 20, 2026
    Arun Menawat        
             
    /s/ Brian Posner   Director   May 20, 2026
    Brian Posner        
             
    /s/ Stella Vnook     Director   May 20, 2026
    Stella Vnook        

     

    II-3

     

    Get the next $AIFF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIFF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIFF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Lipschitz Gregory claimed ownership of 403,707 shares (SEC Form 3)

    3/A - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

    3/13/26 4:30:04 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    President and COO Decaprio David was granted 44,872 shares, increasing direct ownership by 136% to 77,866 units (SEC Form 4)

    4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

    3/12/26 4:30:05 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    Chief Executive Officer Lipschitz Gregory was granted 65,988 shares, increasing direct ownership by 14% to 530,184 units (SEC Form 4)

    4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

    3/12/26 4:30:03 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    $AIFF
    SEC Filings

    View All

    SEC Form S-8 filed by Firefly Neuroscience Inc.

    S-8 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

    5/20/26 8:30:46 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    SEC Form S-3 filed by Firefly Neuroscience Inc.

    S-3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

    5/20/26 8:00:45 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    Firefly Neuroscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

    5/12/26 4:30:16 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    $AIFF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

    – Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder ("PTSD") using brain scans collected on its FDA-510(k)-cleared Evoke System. The biomarker discovery emanates partly from Firefly's previously announced public-private partnership with the U.S. Department of War ("DoW") to support the assessment and treatment of active-duty

    6/2/26 7:40:00 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World's First Known 200,000+ Standardized EEG/ERP Depository

    - Firefly's total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters - - Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, enabling new AI-driven biomarker discovery capabilities – - Milestone supports Firefly's goal of building and launching the world's first EEG/ERP-based foundation model of the human brain - KENMORE, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and

    4/13/26 7:45:00 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    Firefly Confirms Public-Private Partnership with the Department of War

    Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of Company's Commercial Footprint into the U.S. Government and Defense Health Sectors KENMORE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (NASDAQ:AIFF) ("Firefly," or the "Company"), today announced a partnership with the Department of War ("DoW") to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder ("PTSD") and/or Traumatic Brain Injury ("TBI"). The genesis of this innovative public-private

    3/26/26 7:45:00 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    $AIFF
    Financials

    Live finance-specific insights

    View All

    Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

    Company successfully listed on Nasdaq under the symbol "AIFF" Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering wi

    11/14/24 5:30:18 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    $AIFF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Firefly Neuroscience Inc.

    SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

    9/19/24 9:48:56 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Firefly Neuroscience Inc.

    SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

    8/21/24 6:07:51 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Firefly Neuroscience Inc.

    SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

    8/21/24 6:03:49 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    $AIFF
    Leadership Updates

    Live Leadership Updates

    View All

    Stran & Company Appoints Veteran Financial Executive Brian M. Posner to its Board of Directors

    Quincy, MA, July 10, 2025 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ:SWAG) (NASDAQ:SWAGW), a leading provider of outsourced marketing solutions specializing in promotional products and loyalty incentives, today announced the appointment of Brian M. Posner, MBA, to its Board of Directors. Mr. Posner will serve as Chairman of the Audit Committee. Brian Posner brings over four decades of public company financial leadership, strategic planning, and investor relations experience to the Company. Currently, Mr. Posner serves on the Board of Directors of Firefly Neuroscience, Inc. (NASDAQ:AIFF), where he also chairs the Audit Committee. Firefly is an artificial

    7/10/25 8:00:00 AM ET
    $AIFF
    $SWAG
    Computer Software: Prepackaged Software
    Technology
    Advertising
    Consumer Discretionary

    Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

    TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of current director of the Board, Greg Lipschitz, as Executive Chairman, effective as of December 3, 2024. "I look forward to taking on a more active leadership role as Executive Chairman," said Greg Lipschitz, newly appointed Executive Chairman of Firefly. "I believe that Firefly is uniquely positioned at the intersection of artificial intelligence and brain health that I have l

    12/4/24 9:00:00 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology

    Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors

    TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of Stella Vnook, Ph.D. to its Board of Directors, effective as of August 19, 2024. Dr. Vnook will serve as Chairperson of the Nominating Committee. Dr. Vnook brings over 25 years of experience as a distinguished pharmaceutical executive, serial entrepreneur, CEO and founder of multiple biotech companies and visionary leader with a track record of success in biotechnology and life

    9/5/24 9:00:00 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology